-
Media ReleaseSandoz completes acquisition of leading antifungal agent Mycamine® from Astellas, reinforcing leading global anti-infectives portfolio
-
Media ReleaseSandoz receives FDA approval for Tyruko® (natalizumab-sztn), first and only FDA-approved biosimilar for relapsing forms of multiple sclerosis
-
Media ReleaseNovartis publie l’invitation à l’AGE et la brochure d’information aux actionnaires. Sandoz publie le prospectus de cotation avant le vote sur la proposition de scission
-
Media ReleaseNovartis issues EGM Invitation and Shareholder Information Brochure. Sandoz publishes Listing Prospectus ahead of proposed Spin-off vote
-
Media ReleaseNovartis publiziert Einladung und Aktionärsbroschüre zur ausserordentlichen Generalversammlung. Sandoz veröffentlicht den Kotierungsprospekt im Vorfeld der Abstimmung zum vorgeschlagenen Spin-off
-
Media ReleaseSandoz announces plans to build a Biosimilar Technical Development Center in Slovenia to support future growth of biosimilar pipeline
-
Media ReleaseSandoz introduces Act4Biosimilars Action Plan to accelerate patient access to biosimilar medicines
-
Media ReleaseSandoz presents compelling investment proposition as standalone company at Capital Markets Day
-
Media ReleaseSandoz strengthens pipeline expansion through partnership to develop and manufacture multiple biosimilars
-
Media ReleaseSandoz to exclusively commercialize six products in the US, reinforcing global leadership position in off-patent medicines
-
Media ReleaseSandoz receives approval by European Commission for Hyrimoz® (adalimumab) high-concentration formulation
-
Media ReleaseSandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation